A Phase 2/3 interventional study of microneedling and Oral tranexamic acid in Melasma, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Assiut University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing Tranexamic Acid in Melanosis — 6 open to participants now, 7 under way, 2 of them phase 3. Tranexamic Acid · Melanosis.
Among the 16 studies testing Tranexamic Acid in Melanosis, this one is the 11th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 2/3, and was the 14th registered.
170 studies on the registry are indexed under Melanosis; 46 are open to participants now.
Browse Melanosis studies →6 of the 16 studies testing Tranexamic Acid in Melanosis are open now, in 3 countries. Recruiting first, the newest first:
Egymedicalpedia · Sites in Egypt
Ages 18–40
Dr.dr.Irma Bernadette, SpKK (K) · Sites in Indonesia
Ages 30–60 · Women only · Healthy volunteers
Sameh Sarsik · Sites in Egypt
Ages 18+ · Women only
Hina Malik · Sites in Pakistan
Ages 18–50
Allied Hospital Faisalabad · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 19 Melanosis studies recruiting now, 8 (42%) set no upper age limit and 11 (58%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5 · Phase 4 3
First in 2016; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 40 across 157 interventional studies indexed under Melanosis.
Median enrollment 52 across the 16 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
11 studies in Melanosis by Assiut University: 3 open now, 3 under way, 1 of them phase 3.
Among the 11 studies in Melanosis by Assiut University, this one is the 4th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 2/3, and was the 11th registered.
Assiut University’s Melanosis studies by the year they started, since 2017.
3 of the studies testing Tranexamic Acid in Melanosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07448415Phase 3Assiut UniversityEvaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma | 2027-02 |
| NCT07881328Allied Hospital FaisalabadBaseline Dermoscopic Vascular Score and Response to Oral Tranexamic Acid in Facial Melasma | 2027-06 |
| NCT07696806Sameh SarsikMicroneedling-Assisted Metformin, Tranexamic Acid, and Modified Kligman's Formula for Melasma | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing Tranexamic Acid in Melanosis, from their registry updates:
Among Assiut University’s 11 in Melanosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, the investigators evaluate the potential efficacy of TXA alone and microneedling assisted with glutathione alone versus combination of oral tranexamic acid and glutathione-assisted microneedling in the treatment of melasma
Melasma is a chronic, acquired, frequent relapsing and cosmetically disfiguring disorder of hypermelanosis, characterized by light to dark brown hyperpigmentation mostly in sun exposed areas, affected predominantly middle aged females particularly those with darker skin, multiple factors have been postulated to involve in the etiology and pathogenesis of melasma like ; pregnancy, genetics, sun exposure and skin inflammation .Melasma significantly affect quality of life and self-steem of the patients due to its disfigurity appearance.
Although melasma has been widely studied, the treatment still met with difficulty, various therapeutic approaches were tried in treatment of melasma including topical and systemic treatments, chemical peeling, and laser therapy, however none have shown sustained results with incomplete clearance and frequent recurrences.
There has been interest lately in oral medications like tranexamic acid (TXA ) to improve melasma, oral TXA is a synthetic derivative of the amino acid lysine, lysine is an antifibrinolytic agent, procoagulant and approved by FDA for the treatment of cyclic heavy menstrual bleeding, oral TRX acid has been used off-label in dermatology for treatment of hyperpigmentation disorders
.
Also glutathione(GSH) is an option in treatment of melasma, GSH is endogenous tripeptide composed of cysteine, glycine, and glutamate, and serves as a key component of the cellular antioxidant defenCe system by scavenging free radicals and reducing oxidative stress it is considered as skin lightening agent, its major mechanism by inhibition of tyrosinase, tyrosinase inhibition effect indirectly as anti-oxidant agent.
Microneedling is a well-known and established approach for drug delivery applied to treat various skin issues, including melasma. Existing studies indicate that microneedling is an effective adjuvant topical therapy for melasma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
female patients
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will include 14 patients with facial melasma. They will be treated by combined * oral tranexamic acid (250 mg) twice a day for 3 months * microneedling assisted with glutathione every 4 weeks for a maximum of 3 months.
Device: microneedling · Drug: Oral tranexamic acid · Other: Glutathione
will include 14 patients, they will be treated by microneedling assisted with glutathione every 4 weeks for a maximum of 3 months.
Device: microneedling · Other: Glutathione
will include 14 patients, they will be treated by * oral TXA alone 250mg twice daily for a maximum of 3 months.
Drug: Oral tranexamic acid
with one ml of topical glutathione will be done in group A and B, three consecutive sessions, will be performed by derma pen with 36 needles head, will adjusted 1.5 mm needle length and will moved on stretched skin in four directions several times till erythema and pinpoint developed before and after topical application of GTH.
The patient will take oral tranexamic acid 250mg twice daily for 3 months
investigators will use topical GSH solution in assist with microneedling to treat melasma
compare reduction of Melasma Area and Severity Index (MASI) score in any treatment modalities
Time frame: From baseline to 12 weeks
identify patient's satisfaction by Patient Self Assessment
Time frame: from baseline to 3 months after treatment
No study locations are listed for this record.
Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid